PSCHvsXBIETF Comparison
VS
Invesco S&P SmallCap Health Care ETF (PSCH) and State Street SPDR S&P Biotech ETF (XBI) belong to the same industry segment: US Health Care. PSCH's top 1 sector exposures are Healthcare. In contrast, XBI's top sector exposures are Healthcare and Finance. PSCH is less expensive with a Total Expense Ratio (TER) of 0.29%, versus 0.35% for XBI. PSCH is up 22.41% year-to-date (YTD) with +$7M in YTD flows. XBI performs better with 32.87% YTD performance, and +$966M in YTD flows. Run a side-by-side ETF comparison of PSCH and XBI below, and assess how they stack up in performance, liquidity, risk, exposure, holdings, and more, helping you select the best ETF for your investments.
Find out how industry players manage ETF portfolios. Discover our library of Model portfolios
PSCH vs XBI performance and flow charts
Performance
Cumulative Flows
Historic performance and flows
Data as of 09/08/2026
| 1M | 3M | YTD | 1Y | 3Y | 5Y | ||
|---|---|---|---|---|---|---|---|
| Perf. | PSCH XBI | -2.45%+2.44% | +17.39%+26.14% | +22.41%+32.87% | +30.31%+72.26% | +37.14%+107.12% | -14.22%+23.20% |
| Flows | PSCH XBI | +$14M+$531M | +$25M+$1.35B | +$7M+$966M | +$2M+$1.73B | -$109M+$26M | -$207M+$1.69B |
Volatility and drawdown
| 3M | 1Y | 3Y | 5Y | ||
|---|---|---|---|---|---|
| Volatility | PSCH XBI | +16.65%+29.80% | +19.66%+27.90% | +21.83%+28.27% | +22.87%+32.90% |
| Max drawdown | PSCH XBI | -3.84%-10.46% | -15.36%-10.46% | -22.80%-32.94% | -45.76%-53.28% |
| Max drawdown duration | PSCH XBI | 20d40d | 168d40d | 488d331d | 1765d1622d |
Trading data
PSCH | XBI | |
Last sale 9/9/2026 at 1:30 PM | $53.71 | $159.38 |
| Previous close 09/08/2026 | $53.92 | $161.93 |
| Consolidated volume 09/08/2026 | ||
| Average volume 30 days | ||
| Average discount or premium 30 days | ||
| Average Bid/Ask spread 30 days |
Replication quality
Data as of August 31, 2026
1-year trailing difference
Create an account to view replication metrics
Join for free
PSCH | XBI | |
|---|---|---|
| Tracking error | ||
| Tracking difference | ||
| 1 year cumulative return difference | ||
| Best | ||
| Worst | ||
| Daily return difference | ||
| Average | ||
| Worst | ||
Advertisement
Main metrics
Last update 9/9/2026 at 1:30 PM
Live
Closed
PSCH | XBI | |
|---|---|---|
| Last price | $53.71 | $159.38 |
| 1D performance | -0.39% | -1.57% |
| AuM | $182.40 M | $11.33 B |
| E/R | 0.29% | 0.35% |
Characteristics
PSCH | XBI | |
|---|---|---|
| Management strategy | Passive | Passive |
| Provider | Invesco | State Street Investment Management |
| Benchmark | S&P SmallCap 600 Capped Health Care Index | S&P Biotechnology Select Industry Index |
| N° of holdings | 69 | 149 |
| Asset class | Equities | Equities |
| Trailing 12m distribution yield | Join | Join |
| Inception date | April 7, 2010 | January 31, 2006 |
| ESG | No | No |
Advertisement
Exposure
Countries
PSCH
USA
95.04%
Other
4.96%
XBI
USA
95.3%
Other
4.7%
Sectors
PSCH
Healthcare
100%
Other
0%
XBI
Healthcare
99.41%
Other
0.59%
Advertisement
Diversification
PSCH
Total weight of top 15 holdings out of 15
48.1%
XBI
Total weight of top 15 holdings out of 15
20.29%
Top 15 holdings
Data as of July 31, 2026
PSCH
Glaukos Corp.
4.96%
Corcept Therapeutics, Inc.
4.64%
Alkermes Plc
4.21%
Protagonist Therapeutics, Inc.
4.20%
TG Therapeutics, Inc.
3.68%
PTC Therapeutics, Inc.
3.23%
Liquidia Corp.
3.19%
Teleflex, Inc.
3.11%
Ligand Pharmaceuticals, Inc.
3.01%
Indivior Pharmaceuticals, Inc.
2.55%
Merit Medical Systems, Inc.
2.52%
RadNet, Inc.
2.34%
Veracyte, Inc.
2.32%
ICU Medical, Inc.
2.17%
Concentra Group Holdings Parent, Inc.
1.96%
XBI
Apogee Therapeutics, Inc.
1.65%
Oruka Therapeutics, Inc.
1.53%
Dianthus Therapeutics, Inc.
1.42%
Erasca, Inc.
1.38%
Twist Bioscience Corp.
1.37%
Kymera Therapeutics, Inc.
1.34%
Spyre Therapeutics, Inc.
1.33%
Revolution Medicines, Inc.
1.32%
CG Oncology, Inc.
1.32%
Protagonist Therapeutics, Inc.
1.31%
Praxis Precision Medicines, Inc.
1.30%
Regeneron Pharmaceuticals, Inc.
1.29%
Cogent Biosciences, Inc.
1.26%
Natera, Inc.
1.26%
Arrowhead Pharmaceuticals, Inc.
1.22%
Frequently asked questions about PSCH and XBI
How have the PSCH and XBI ETFs performed in 2026?
As of September 8, 2026, PSCH is up 22.41% year-to-date (YTD), while XBI has returned 32.87%. That puts XBI better performer ahead so far this year.
Which ETF is attracting more investor money: PSCH or XBI?
Year-to-date, the PSCH ETF saw +$7M in flows, compared to +$966M for XBI.
Which ETF is more volatile: PSCH or XBI?
Over the past year, PSCH had a volatility of 19.66%, while XBI experienced 27.9%.
Which ETF is bigger: PSCH or XBI?
As of September 8, 2026, PSCH holds $182.40 M in assets under management (AUM), while XBI manages $11.33 B.
What sectors do the PSCH and XBI ETFs invest in?
PSCH leans toward sectors like Healthcare. Meanwhile, XBI focuses on Healthcare.
What are the top holdings of the PSCH ETF and XBI ETF?
PSCH top holdings include Glaukos Corp., Corcept Therapeutics, Inc. and Alkermes Plc. XBI holds in its top three: Apogee Therapeutics, Inc., Oruka Therapeutics, Inc. and Dianthus Therapeutics, Inc..
Which ETF is more diversified: PSCH or XBI?
PSCH holds 69 securities with 48.1% of its assets in the top 15. XBI has 151 securities and a top 15 weight of 20.29%.
Advertisement
Latest news about PSCH & XBI
Small-Cap Biotech ETFs: High-Risk, High-Reward Opportunities
September 18, 2025
XBI
Are Biotechnology ETFs In the Midst of a Comeback?
August 20, 2025
XBI
Two biotech ETFs to watch for the rest of 2022 and beyond
September 13, 2022
XBI
Biotech ETFs – Investing in Health Innovation
July 21, 2022
XBI
Advertisement
Advertisement
